Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Shares of HBPCF stock remained flat at $0.77 on Friday. The firm has a market cap of $58.81 million, a PE ratio of -19.25 and a beta of 0.11. Helix Biopharma has a 52-week low of $0.77 and a 52-week high of $1.73. The stock has a 50-day moving average of $1.26 and a 200-day moving average of $1.61.
Helix Biopharma Company Profile
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.
Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth.
Further Reading
- Five stocks we like better than Helix Biopharma
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
- SaaS-Pocalypse II: Is ServiceNow’s Sell-Off Another Buying Opportunity?
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
